Aligned Genetics, Inc.
Financials
Valuation Metrics
Aligned Genetics, Inc.'s Market Cap is ₩369B. At end of 2025 it was ₩550B. Ranked #1935 of 2,411 in KR market (top 80%), #1210 of 1,632 on KOSDAQ (top 74%), #205 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 89%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 36.90B KRW | KR#1,935/2,411 Sec#205/231 |
| Revenue | 16.16B KRW | KR#2,190/2,411 Sec#163/231 |
| Net Income | 4.64B KRW | KR#1,242/2,411 Sec#85/231 |
| Total Assets | 60.44B KRW | KR#2,097/2,411 Sec#183/231 |
| Net Assets | 39.20B KRW | KR#2,059/2,411 Sec#181/231 |
| Employees | 66 | KR#1,916/2,411 Sec#168/231 |
| Value | ||
| P/E | 7.95x | KR#678/2,411 Sec#30/231 |
| P/B | 0.94x | KR#1,438/2,411 Sec#90/231 |
| PEG | 0.20x | KR#567/2,411 Sec#33/231 |
| P/S | 2.28x | KR#1,889/2,411 Sec#109/231 |
| EV/EBITDA | 15.74x | KR#900/2,411 Sec#54/231 |
| FCF Yield | -3.28% | KR—/2,411 Sec—/231 |
| Profitability | ||
| ROE | 11.84% | KR#486/2,411 Sec#33/231 |
| ROA | 7.68% | KR#462/2,411 Sec#36/231 |
| Op. Margin | 15.63% | KR#278/2,411 Sec#26/231 |
| Revenue Growth | -5.88% | KR#1,806/2,411 Sec#172/231 |
| Earnings Growth | 39.94% | KR#598/2,411 Sec#38/231 |
| Financial Health | ||
| Debt Ratio | 54.17% | KR#1,020/2,411 Sec#119/231 |
| Total Debt | 14.31B KRW | KR#1,505/2,411 Sec#129/231 |
| FCF | -1.21B KRW | KR#1,291/2,411 Sec#99/231 |
| Cash | 11.44B KRW | KR#1,621/2,411 Sec#138/231 |
| Current Ratio | 5.43x | KR#253/2,411 Sec#48/231 |
| Net Debt/EBITDA | 1.14x | KR#751/2,411 Sec#51/231 |
| Performance | ||
| 1Y Return | -22.31% | KR#1,316/2,411 Sec#98/231 |
| 1M Return | -3.71% | KR#1,901/2,411 Sec#182/231 |
| From 52W High | -57.11% | KR#1,630/2,411 Sec#135/231 |
| 1Y MDD | -60.50% | KR#1,475/2,411 Sec#120/231 |
| Trading | ||
| Volume | 5,490 shares | KR#1,548/2,411 Sec#161/231 |
| Trading Value | 14.0M KRW | KR#1,755/2,411 Sec#191/231 |
| Foreign Own. | 2.57% | KR#1,429/2,411 Sec#134/231 |
| Per Share | ||
| EPS | 326 KRW | KR#1,138/2,411 Sec#78/231 |
| BPS | 2,757 KRW | KR#1,922/2,411 Sec#149/231 |
Company Info
Alligned, established in 2008 as a technology venture company developing, producing, and selling advanced equipment and reagents for life science research and diagnostics worldwide, was listed on the KOSDAQ market in 2016. It operates overseas sales corporations and branches in the United States, Europe, and Japan. Based on convergence technologies including bio, optics, electricity, electronics, and software, its main products are automatic cell counting systems, biological tissue clearing and imaging systems, and digital cell imaging systems.